Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.6632
-0.0114 (-1.69%)
At close: Aug 7, 2025, 4:00 PM
0.6699
+0.0067 (1.01%)
Pre-market: Aug 8, 2025, 5:10 AM EDT
-1.69%
Market Cap107.88M
Revenue (ttm)n/a
Net Income (ttm)-99.62M
Shares Out 162.67M
EPS (ttm)-0.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,935,554
Open0.6800
Previous Close0.6746
Day's Range0.6459 - 0.7098
52-Week Range0.3600 - 4.0100
Beta3.01
AnalystsStrong Buy
Price Target8.60 (+1,196.74%)
Earnings DateAug 6, 2025

About CHS

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved eject... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 97
Stock Exchange NASDAQ
Ticker Symbol TNYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $8.6, which is an increase of 1,196.74% from the latest price.

Price Target
$8.6
(1,196.74% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™ -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts

1 day ago - GlobeNewsWire

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of  TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from  Cohort 1 and Initial Data from Cohort 2 Expec...

8 days ago - GlobeNewsWire

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

3 months ago - GlobeNewsWire

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of ...

3 months ago - GlobeNewsWire

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene

3 months ago - GlobeNewsWire

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201;  RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Sev...

4 months ago - GlobeNewsWire

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...

4 months ago - GlobeNewsWire

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 ...

5 months ago - GlobeNewsWire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

5 months ago - GlobeNewsWire

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...

5 months ago - GlobeNewsWire

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...

5 months ago - GlobeNewsWire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...

5 months ago - GlobeNewsWire

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Funding will Support Ongoing RIDGE™ -1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

6 months ago - GlobeNewsWire

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies  for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBP...

7 months ago - GlobeNewsWire

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET

8 months ago - GlobeNewsWire

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy

9 months ago - GlobeNewsWire

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling

10 months ago - GlobeNewsWire

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...

1 year ago - GlobeNewsWire

Tenaya Therapeutics Announces Research Leadership Updates

Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role

1 year ago - GlobeNewsWire

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...

1 year ago - GlobeNewsWire

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024

1 year ago - GlobeNewsWire

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya's Continued ...

1 year ago - GlobeNewsWire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-as...

1 year ago - GlobeNewsWire

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

1 year ago - GlobeNewsWire

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and  Improved Diastolic Heart Function Alone or in Combination with  SGLT2 Inhibitor in Murine Models of Disease

1 year ago - GlobeNewsWire